Cargando…

A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex

Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against my...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ju Mi, Park, Jiyun, Choi, Sangwon, Jhun, Byung Woo, Kim, Su-Young, Jo, Kyung-Wook, Hong, Jung Joo, Kim, Lee-Han, Shin, Sung Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841306/
https://www.ncbi.nlm.nih.gov/pubmed/33519787
http://dx.doi.org/10.3389/fmicb.2020.626216
_version_ 1783643777640955904
author Lee, Ju Mi
Park, Jiyun
Choi, Sangwon
Jhun, Byung Woo
Kim, Su-Young
Jo, Kyung-Wook
Hong, Jung Joo
Kim, Lee-Han
Shin, Sung Jae
author_facet Lee, Ju Mi
Park, Jiyun
Choi, Sangwon
Jhun, Byung Woo
Kim, Su-Young
Jo, Kyung-Wook
Hong, Jung Joo
Kim, Lee-Han
Shin, Sung Jae
author_sort Lee, Ju Mi
collection PubMed
description Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against mycobacterial infection. We performed a comparison between the standard regimen and an alternative regimen (replacing the rifampicin of the standard regimen with clofazimine) based on the intracellular anti-MAC activities of the individual drugs in a murine model of chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC activities of the individual drugs and their combinations in murine bone marrow-derived macrophages (BMDMs) were determined. The treatment efficacies of the standard and clofazimine-containing regimens were evaluated in mice chronically infected with M. avium by initiating 2- and 4-week treatment at 8 weeks post-infection. Bacterial loads in the lung, spleen, and liver were assessed along with lung inflammation. Insufficient intracellular anti-MAC activity of rifampicin in BMDMs was recorded despite its low in vitro minimum inhibitory concentrations (MICs), whereas optimal intracellular killing activity against all tested MAC strains was achieved with clofazimine. Compared to the standard regimen, the clofazimine-containing regimen significantly reduced CFUs in all organs and achieved marked reductions in lung inflammation. The replacement of rifampicin with clofazimine in the treatment regimen resulted in more favorable outcomes in an animal model of chronic progressive MAC-PI. Intriguingly, 2 weeks of treatment with the clofazimine-containing regimen reduced bacterial loads more effectively than 4 weeks of treatment with the standard regimen in M. avium-infected mice. Thus, the clofazimine-containing regimen also had a treatment-shortening effect.
format Online
Article
Text
id pubmed-7841306
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78413062021-01-29 A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex Lee, Ju Mi Park, Jiyun Choi, Sangwon Jhun, Byung Woo Kim, Su-Young Jo, Kyung-Wook Hong, Jung Joo Kim, Lee-Han Shin, Sung Jae Front Microbiol Microbiology Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for Mycobacterium avium complex-pulmonary disease (MAC-PD) remain unsatisfactory. Thus, improved treatment regimens for MAC-PD are required. Clofazimine has recently been revisited as an effective drug against mycobacterial infection. We performed a comparison between the standard regimen and an alternative regimen (replacing the rifampicin of the standard regimen with clofazimine) based on the intracellular anti-MAC activities of the individual drugs in a murine model of chronic progressive MAC-pulmonary infection (MAC-PI). The intracellular anti-MAC activities of the individual drugs and their combinations in murine bone marrow-derived macrophages (BMDMs) were determined. The treatment efficacies of the standard and clofazimine-containing regimens were evaluated in mice chronically infected with M. avium by initiating 2- and 4-week treatment at 8 weeks post-infection. Bacterial loads in the lung, spleen, and liver were assessed along with lung inflammation. Insufficient intracellular anti-MAC activity of rifampicin in BMDMs was recorded despite its low in vitro minimum inhibitory concentrations (MICs), whereas optimal intracellular killing activity against all tested MAC strains was achieved with clofazimine. Compared to the standard regimen, the clofazimine-containing regimen significantly reduced CFUs in all organs and achieved marked reductions in lung inflammation. The replacement of rifampicin with clofazimine in the treatment regimen resulted in more favorable outcomes in an animal model of chronic progressive MAC-PI. Intriguingly, 2 weeks of treatment with the clofazimine-containing regimen reduced bacterial loads more effectively than 4 weeks of treatment with the standard regimen in M. avium-infected mice. Thus, the clofazimine-containing regimen also had a treatment-shortening effect. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7841306/ /pubmed/33519787 http://dx.doi.org/10.3389/fmicb.2020.626216 Text en Copyright © 2021 Lee, Park, Choi, Jhun, Kim, Jo, Hong, Kim and Shin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Lee, Ju Mi
Park, Jiyun
Choi, Sangwon
Jhun, Byung Woo
Kim, Su-Young
Jo, Kyung-Wook
Hong, Jung Joo
Kim, Lee-Han
Shin, Sung Jae
A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title_full A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title_fullStr A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title_full_unstemmed A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title_short A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
title_sort clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the mycobacterium avium complex
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841306/
https://www.ncbi.nlm.nih.gov/pubmed/33519787
http://dx.doi.org/10.3389/fmicb.2020.626216
work_keys_str_mv AT leejumi aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT parkjiyun aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT choisangwon aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT jhunbyungwoo aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT kimsuyoung aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT jokyungwook aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT hongjungjoo aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT kimleehan aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT shinsungjae aclofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT leejumi clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT parkjiyun clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT choisangwon clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT jhunbyungwoo clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT kimsuyoung clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT jokyungwook clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT hongjungjoo clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT kimleehan clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex
AT shinsungjae clofaziminecontainingregimenconfersimprovedtreatmentoutcomesinmacrophagesandinamurinemodelofchronicprogressivepulmonaryinfectioncausedbythemycobacteriumaviumcomplex